Skip to main content

Axonics Stock Forecast, Price & News

-0.67 (-1.29 %)
(As of 05/13/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.11 million shs
Average Volume566,484 shs
Market Capitalization$2.15 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Axonics logo

About Axonics

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.


See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:AXNX
Year FoundedN/A

Sales & Book Value

Annual Sales$13.82 million
Book Value$6.40 per share


Net Income$-79,930,000.00




Market Cap$2.15 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.72 out of 5 stars

Medical Sector

246th out of 2,042 stocks

Surgical & Medical Instruments Industry

26th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Axonics (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics
or view top-rated stocks.

What stocks does MarketBeat like better than Axonics?

Wall Street analysts have given Axonics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Axonics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Axonics

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Thursday, May, 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.16. The firm earned $32.90 million during the quarter, compared to the consensus estimate of $27.89 million. Axonics had a negative net margin of 76.62% and a negative trailing twelve-month return on equity of 28.05%. Axonics's quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.43) earnings per share.
View Axonics' earnings history

How has Axonics' stock been impacted by Coronavirus (COVID-19)?

Axonics' stock was trading at $30.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXNX shares have increased by 70.1% and is now trading at $51.39.
View which stocks have been most impacted by COVID-19

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $176 million-$180 million, compared to the consensus revenue estimate of $169.92 million.

What price target have analysts set for AXNX?

7 Wall Street analysts have issued twelve-month price targets for Axonics' stock. Their forecasts range from $57.00 to $77.00. On average, they expect Axonics' stock price to reach $65.75 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts' price targets for Axonics
or view top-rated stocks among Wall Street analysts.

Who are Axonics' key executives?

Axonics' management team includes the following people:
  • Mr. Raymond W. Cohen, CEO & Director (Age 62, Pay $871.2k)
  • Mr. Danny L. Dearen, Pres & CFO (Age 58, Pay $636.2k)
  • Mr. Rinda K. Sama, Chief Operating Officer (Age 42, Pay $536.2k)
  • Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 48)
  • Mr. Neil Bhalodkar, VP of Investor Relations
  • Mr. Aaron Pettit, Gen. Counsel & Chief Compliance Officer
  • Mr. John Woock Ph.D., Chief Marketing Officer (Age 38)
  • Mr. Michael V. Williamson, Sr. VP, Gen. & IP Counsel (Age 50)
  • Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 58)
  • Mr. Prabodh Mathur, Chief Product Devel. Officer (Age 61)

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

Who are some of Axonics' key competitors?

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.56%), Lord Abbett & CO. LLC (4.91%), Bellevue Group AG (3.48%), Waddell & Reed Financial Inc. (2.61%), Oak Ridge Investments LLC (2.53%) and Geode Capital Management LLC (1.25%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics

Which institutional investors are selling Axonics stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Blackcrane Capital LLC, Peregrine Capital Management LLC, Northern Trust Corp, Sei Investments Co., Aviva PLC, Bank of New York Mellon Corp, and HighPoint Advisor Group LLC. Company insiders that have sold Axonics company stock in the last year include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics
or view top insider-selling stocks.

Which institutional investors are buying Axonics stock?

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Lord Abbett & CO. LLC, Principal Financial Group Inc., Bellevue Group AG, Ziegler Capital Management LLC, Federated Hermes Inc., Allianz Asset Management GmbH, and Lisanti Capital Growth LLC. Company insiders that have bought Axonics stock in the last two years include Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics
or or view top insider-buying stocks.

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $51.39.

How much money does Axonics make?

Axonics has a market capitalization of $2.15 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 416 workers across the globe.

What is Axonics' official website?

The official website for Axonics is

Where are Axonics' headquarters?

Axonics is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.